TLDR: Microsoft co-founder Bill Gates is supporting a new $1 million ‘Alzheimer’s Insights AI Prize’ competition. Organized by the Alzheimer’s Disease Data Initiative, the prize aims to spur the development of advanced AI solutions, specifically ‘agentic AI’ systems, to analyze vast amounts of Alzheimer’s data and accelerate breakthroughs in understanding and treating the disease. The winning AI tool will be made freely available to global researchers.
In a significant philanthropic endeavor at the intersection of technology and healthcare, Microsoft co-founder Bill Gates has announced his support for the ‘Alzheimer’s Insights AI Prize,’ a $1 million competition designed to revolutionize Alzheimer’s disease research. This initiative seeks to harness the power of artificial intelligence to accelerate scientific discovery and therapeutic development for Alzheimer’s and related dementias, which currently affect over 55 million people worldwide.
The competition is spearheaded by the Alzheimer’s Disease Data Initiative (ADDI), a global non-profit coalition dedicated to advancing scientific research in this critical area. The core objective is to incentivize the creation of ‘agentic AI’ systems – AI that can autonomously plan, reason, and act – to significantly enhance the speed, scale, and scope of research by analyzing decades of existing global patient data. The ultimate goal is to make the winning solution freely accessible to researchers on the ADDI platform, fostering collaborative advancements across the scientific community.
While recent progress in diagnostics and treatments offers a glimmer of hope, there remains substantial untapped potential to accelerate the pace of scientific discovery. The ‘Alzheimer’s Insights AI Prize’ aims to unlock this potential by leveraging cutting-edge AI capabilities.
The competition follows a structured timeline: The application portal is currently open, with submissions due by September 12th, 2025, at 11:59 PM PT. Up to eight semi-finalist teams will be selected and announced on October 3rd, 2025. These teams will then be required to submit their product prototypes by November 21st, 2025, at 11:59 PM PT, and will present their innovations at a pitch event held in conjunction with the Clinical Trials on Alzheimer’s Disease (CTAD) Conference during the week of December 1st, 2025, in San Diego, California, USA. Semi-finalist presentations will include a 10-minute pitch and a brief product demonstration, followed by a five-minute Q&A session with the judging panel.
Also Read:
- AI Supremacy Race Intensifies: Tech Giants Pour Billions Amidst Bubble Concerns
- Pi Network’s $100 Million AI Initiative and Pi Coin’s Market Position
Following the semi-final stage, up to three finalist teams will be announced on December 5th, 2025. These finalists will be invited to present at the AD/PD International Conference during the week of March 16th, 2026, in Copenhagen, Denmark. Finalist presentations will consist of a 10-minute product demonstration followed by a 10-minute Q&A with the judging panel. Travel and presentation support will be provided for both the semi-finalist and finalist live events, with a maximum of two presenters per team. The grand prize winner will be declared during the conference week in Copenhagen.
